Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
EARLY_PHASE1
22
about 1.1 years
18–80
1 site in CT
What this study is about
This trial is testing a new imaging drug called [18F]MK-0947 to see if it can help doctors visualize changes in the brain related to Parkinson's disease (PD). The drug works with PET scans to show areas of the brain where α-synuclein builds up, which is linked to PD. The trial aims to determine if [18F]MK-0947 is safe and effective for visualizing α-synuclein in the brain.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]MK-0947
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety of [18F]MK-0947: Incidence of Adverse Events
Secondary: Model-derived Pharmacokinetics of [18F]MK-0947
Neurology